Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Global cancer rates are expected to rise 77% by 2050
View:
Post by Noteable on Feb 03, 2024 6:19pm

Global cancer rates are expected to rise 77% by 2050

February 01, 2024 - " An estimated 20 million cases of cancer were diagnosed worldwide in 2022, up from 18 million in 2020. That number will rise by 77% to 35 million by 2050, the World Health Organization’s International Agency for Research on Cancer (IARC) predicted Thursday."

https://fortune.com/well/2024/02/01/global-cancer-rates-rise-world-health-organization-aging-alcohol/
Comment by Noteable on Feb 03, 2024 6:28pm
"Cancer patients are “increasingly shifting from older to middle-aged individuals,” according to a report released Wednesday by the American Cancer Society. Among adults 65 and older, adults 50 to 64 and those younger than 50, “people aged younger than 50 years were the only one of these three age groups to experience an increase in overall cancer incidence” from 1995 to 2020, says the ...more  
Comment by Noteable on Apr 04, 2024 12:06pm
April 04, 2024 -  Oncology Clinical Trials Market Experiencing Rapid Growth.  The U.S. oncology clinical trials market size was valued at USD 3.82 billion in 2023 and is expected to reach around USD 6.49 billion by 2033, growing at a CAGR of 5.50% from 2024 to 2033. An increase in funding from pharmaceutical and biotech companies, non-profit organizations, and CROs for oncology ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities